BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driv

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven p

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven p

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st

PR Audio: BROOMFIELD, Colo., June 8, 2026 – PRISM MediaWire (Press Release Service – Press Release D

BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”)

BROOMFIELD, Colo., June 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distributio

BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st

Broomfield, CO, June 3, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution)

Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience group Add

Award-winning, NIH funded study indicates that immune-associated biological signatures may play a ro

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a commercial-s

Award-winning, NIH funded study indicates that immune-associated biological signatures may play a ro

Top Wall Street analysts changed outlook on top names. For full changes, see analyst ratings page. S

Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and raises the

BROOMFIELD, Colo., May 28, 2026 – PRISM MediaWire (Press Release Service – Press Release Distributio

BROOMFIELD, Colo., May 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (N

Offers $4.00 per share in cash plus CVRStock currently trades below the value of its cash and other

Offers $4.00 per share in cash plus CVR Stock currently trades below the value of its cash and other

Aclarion (ACON) might move higher on growing optimism about its earnings prospects, which is reflect

Aclarion, Inc. (ACON) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus E

Aclarion (NASDAQ:ACON) reported quarterly losses of $(1.34) per share which beat the analyst consens

BROOMFIELD, Colo., May 07, 2026 – PRISM MediaWire (Press Release Service – Press Release Distributio

Lanman Spinal Neurosurgery is a leading spine-focused private practice recognized for its expertise

“Matching the right procedure to the right patient is what moves the field forward” Lanman Spinal Ne

Expansion of the commercial team reflects increasing demand for Nociscan, supported by triple-digit

BROOMFIELD, Colo., May 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (N

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st

Patent covers use of AI in workflows of future products to accelerate company's ability to scale

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st

Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and lowers the

Aclarion, Inc. (NASDAQ:ACON, ACONW))) ("Aclarion" or the "Company") today announced

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a commercial-s

Expands availability of Nociscan in the greater Los Angeles areaReinforces Nociscan's non-invasi

Aclarion, Inc. (NASDAQ: ACON) closed a $10.4 million financing at $5.18/share, boosting balance shee

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st

Aclarion Inc. (NASDAQ: ACON) provided a corporate update on Thursday, reporting strong commercial mo

ACON: 54% | Aclarion Reports Triple-Digit Growth for AI Back Pain Platform as Nociscan Adoption Acce

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st

Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a succes